WO2004034062A3 - Regulation de cap-1 - Google Patents

Regulation de cap-1 Download PDF

Info

Publication number
WO2004034062A3
WO2004034062A3 PCT/GB2003/004341 GB0304341W WO2004034062A3 WO 2004034062 A3 WO2004034062 A3 WO 2004034062A3 GB 0304341 W GB0304341 W GB 0304341W WO 2004034062 A3 WO2004034062 A3 WO 2004034062A3
Authority
WO
WIPO (PCT)
Prior art keywords
asthma
cap
therapy
polypeptide
agents
Prior art date
Application number
PCT/GB2003/004341
Other languages
English (en)
Other versions
WO2004034062A2 (fr
Inventor
Kevin Bruce Bacon
Herath Mudiyanselage At Herath
Ningshu Liu
Peter Reinemer
Christian Rohlff
Original Assignee
Oxford Glycosciences Uk Ltd
Bayer Healthcare Ag
Kevin Bruce Bacon
Herath Mudiyanselage At Herath
Ningshu Liu
Peter Reinemer
Christian Rohlff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Glycosciences Uk Ltd, Bayer Healthcare Ag, Kevin Bruce Bacon, Herath Mudiyanselage At Herath, Ningshu Liu, Peter Reinemer, Christian Rohlff filed Critical Oxford Glycosciences Uk Ltd
Priority to AU2003269257A priority Critical patent/AU2003269257A1/en
Publication of WO2004034062A2 publication Critical patent/WO2004034062A2/fr
Publication of WO2004034062A3 publication Critical patent/WO2004034062A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des procédés permettant de traiter des maladies inflammatoires, y compris des maladies respiratoires, telles que l'asthme et des états liés à l'asthme, ces procédés consistant, entre autres, à réguler le polypeptide (protéine 1 associée à l'adénylyl-cyclase/CAP-1). La présente invention se rapporte en outre à des agents modulant l'expression ou l'activité de ce polypeptide, à des procédés d'identification de ces agents ainsi qu'à l'utilisation de CAP-1 dans le diagnostic de maladies inflammatoires, y compris de maladies respiratoires, telles que l'asthme et des états liés à l'asthme.
PCT/GB2003/004341 2002-10-08 2003-10-08 Regulation de cap-1 WO2004034062A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003269257A AU2003269257A1 (en) 2002-10-08 2003-10-08 Use of cap-1 for the therapy of asthma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0223272A GB0223272D0 (en) 2002-10-08 2002-10-08 A protein involved in therapy
GB0223272.6 2002-10-08

Publications (2)

Publication Number Publication Date
WO2004034062A2 WO2004034062A2 (fr) 2004-04-22
WO2004034062A3 true WO2004034062A3 (fr) 2004-06-03

Family

ID=9945455

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/004341 WO2004034062A2 (fr) 2002-10-08 2003-10-08 Regulation de cap-1

Country Status (3)

Country Link
AU (1) AU2003269257A1 (fr)
GB (1) GB0223272D0 (fr)
WO (1) WO2004034062A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2414397A1 (fr) * 2009-03-30 2012-02-08 Protab Ltd. Protéine associée à l'adénylyle cyclase (cap1) et ses utilisations comme cible pour l'immunomodulation
WO2013022262A2 (fr) * 2011-08-08 2013-02-14 서울대학교병원 Récepteur de résistine humaine, et utilisation de celui-ci
US9933424B2 (en) 2011-08-08 2018-04-03 Seoul National University Hospital Human resistin receptor and use thereof
KR102040974B1 (ko) * 2017-01-31 2019-11-06 서울대학교병원 Cap1로부터 유래된 폴리펩티드 및 이를 유효성분으로 포함하는 약학적 조성물
WO2021177518A1 (fr) * 2020-03-02 2021-09-10 서울대학교병원 Composition pharmaceutique pour abaisser le cholestérol sanguin, prévenir ou traiter des maladies cardiovasculaires et réduire l'inflammation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002757A2 (fr) * 2000-06-29 2002-01-10 Incyte Genomics, Inc. Adenylyl et guanylyl cyclases
WO2002048397A2 (fr) * 2000-12-11 2002-06-20 Bayer Aktiengesellschaft Regulation d'adenylate cyclase humaine de type vii
WO2002072129A1 (fr) * 2001-03-09 2002-09-19 Paula Sundstrom Methodes de regulation de transitions bud-hypha et de niveaux de camp par le gene proteique cap1 associe a l'adenylate cyclase
WO2003105884A1 (fr) * 2002-06-18 2003-12-24 Oxford Glycosciences (Uk) Ltd Utilisation de la shp-1 dans la therapie de l'asthme

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002757A2 (fr) * 2000-06-29 2002-01-10 Incyte Genomics, Inc. Adenylyl et guanylyl cyclases
WO2002048397A2 (fr) * 2000-12-11 2002-06-20 Bayer Aktiengesellschaft Regulation d'adenylate cyclase humaine de type vii
WO2002072129A1 (fr) * 2001-03-09 2002-09-19 Paula Sundstrom Methodes de regulation de transitions bud-hypha et de niveaux de camp par le gene proteique cap1 associe a l'adenylate cyclase
WO2003105884A1 (fr) * 2002-06-18 2003-12-24 Oxford Glycosciences (Uk) Ltd Utilisation de la shp-1 dans la therapie de l'asthme

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HUBBERSTEY A. ET AL.: "Cyclase-associated proteins : CAPacity for linking signal transduction and actin polymerization.", FASEB J., vol. 16, August 2002 (2002-08-01), pages 487 - 499, XP002273212 *
MANN M. ET AL.: "Analysis of protein phosphorylation using mass spectrometry : deciphering the phosphoproteome", TRENDS BIOTECH., vol. 20, no. 6, June 2002 (2002-06-01), pages 261 - 268, XP004352765 *
PAGE C.P. ET AL.: "Contrasting properties of albuterol stereoisomers.", J. ALLERGY CLIN. IMMUNOL., vol. 104, 1999, pages S31 - S41, XP009027525 *
PAGE M.J. ET AL.: "Proteomics : a major new technology for the drug discovery process.", DRUG DISCOV. TODAY, vol. 4, no. 2, 2 February 1999 (1999-02-02), pages 55 - 62, XP002273211 *

Also Published As

Publication number Publication date
AU2003269257A1 (en) 2004-05-04
WO2004034062A2 (fr) 2004-04-22
AU2003269257A8 (en) 2004-05-04
GB0223272D0 (en) 2002-11-13

Similar Documents

Publication Publication Date Title
WO2003099771A3 (fr) Derives de diaryle-uree utilises pour le traitement des maladies dependant des proteines kinases
WO2003096990A3 (fr) Cages proteiques pour l'administration d'agents therapeutiques et d'imagerie medicale
WO2002074337A8 (fr) Inhibiteurs et/ou antagonistes de proteines hmgb1 destines au traitement de maladies vasculaires
WO2004019884A3 (fr) Agents et procedes pour stimuler la formation osseuse
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
TW329387B (en) Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
WO2005078124A3 (fr) Marqueur diagnostique pour le cancer
MY162068A (en) Formulation of human antibodies for treating tnf-(alpha) associated disorders
WO2002100390A3 (fr) Methode amelioree de traitement du syndrome des facteurs de risque de coronaropathie chez l'etre humain
PL1641483T3 (pl) Białka fuzyjne
WO2006092668A3 (fr) Compositions proteiques de cellules cutanees foetales pour le traitement d'affections, de troubles ou de maladies cutanes et procedes de fabrication et d'utilisation de celles-ci
WO2004041067A3 (fr) Prevention et traitement d'une maladie synucleopathique
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
WO2004074486A3 (fr) Proteines de fusion de muteines d'interferon-alpha aux proprietes ameliorees
WO2005072277A3 (fr) Fragments amides de l'hormone parathyroide et leurs applications
TW200719908A (en) Dermatologic use of milk proteins
WO2004031129A3 (fr) Nouveaux composes destines au traitement des maladies auto-immunes, des maladies immuno-allergiques et des rejets en cas de greffes d'organes ou de tissus
AU6471500A (en) Aqueous nasal formulation
IL171384A (en) Use of slurp-1 in the preparation of medicaments for the treatment of neurological disorders
WO2003011327A3 (fr) Secretine pour le traitement de l'asthme
WO2004055201A3 (fr) Cholesterol 24-hydroxylase (cyp46) utilisee en tant que cible therapeutique pour le traitement de la maladie d'alzheimer
EP1281763A3 (fr) FACTEUR DE TRANSCRIPTION "Early growth response-1" (EGR-1)
WO2004034062A3 (fr) Regulation de cap-1
WO2002046221A3 (fr) Proteines
WO2002051379A3 (fr) Aerosol nasal thixotropique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP